A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors

被引：0
|
作者：
Ratain, M. J.
Benedetti, F. M.
Janisch, L.
Khor, S.
Schilsky, R. L.
Cohen, E. E.
Maitland, M. L.
Elias, L.
LoRusso, P. M.
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Geron Corp, Menlo Pk, CA USA
[3] Wayne State Univ, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3581
引用
收藏
页数：1
相关论文
共 50 条
  • [41] GRN163L, a potent and specific inhibitor of telomerase: Integrated pharmacokinetic, pharmacodynamic, and safety data guides design of practical treatment regimens for targeting inhibitory levels in patients.
    Tressler, Robert J.
    Chin, Allison C.
    Feldman, Eric J.
    Rai, Kanti R.
    Kombrust, Doug
    Harley, Calvin B.
    Behrs, Melissa A. Kelly
    Elias, Laurence
    BLOOD, 2006, 108 (11) : 733A - 733A
  • [42] First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
    Razak, Albiruni R. Abdul
    Mau-Soerensen, Morten
    Gabrail, Nashat Y.
    Gerecitano, John F.
    Shields, Anthony F.
    Unger, Thaddeus J.
    Saint-Martin, Jean R.
    Carlson, Robert
    Landesman, Yosef
    McCauley, Dilara
    Rashal, Tami
    Lassen, Ulrik
    Kim, Richard
    Stayner, Lee-Anne
    Mirza, Mansoor R.
    Kauffman, Michael
    Shacham, Sharon
    Mahipal, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4142 - +
  • [43] Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).
    Plummer, Elizabeth R.
    Dean, Emma Jane
    Evans, T. R. Jeffry
    Greystoke, Alastair
    Herbschleb, Karin
    Ranson, Malcolm
    Brown, Jennifer
    Zhang, Yanqiong
    Karan, Sharon
    Pollard, John
    Penney, Marina S.
    Asmal, Mohammed
    Fields, Scott Z.
    Middleton, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
    Eskens, Ferry A. L. M.
    Ramos, Francisco J.
    Burger, Herman
    O'Brien, James P.
    Piera, Adelaida
    de Jonge, Maja J. A.
    Mizui, Yoshiharu
    Wiemer, Erik A. C.
    Carreras, Maria Josepa
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6296 - 6304
  • [45] Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).
    Kozioff, M.
    Sledge, G. W.
    Benedetti, F. M.
    Starr, A.
    Wallace, J. A.
    Stuart, M. J.
    Gruver, D.
    Miller, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors.
    Dienstmann, R.
    Tolcher, A. W.
    Papadopoulos, K. P.
    Rasco, D. W.
    Tabernero, J.
    Brana, I.
    Piera, A.
    Skartved, N. J.
    Aladdin, H.
    Petersen, J.
    Patnaik, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Biomarker analyses from the Phase I clinical trial of the first-in-class SIRPa immune checkpoint inhibitor BI765063 in patients with advanced solid tumors
    Champiat, Stephane
    Cassier, Philippe A.
    Kotecki, Nuria
    Gomez-Roca, Carlos
    Marabelle, Aurelien
    Vinceneux, Armelle
    Jungels, Christiane
    Elgadi, Mabrouk
    Graeser, Ralph
    Vandewalle, Thomas
    Girault, Isabelle
    Guen, Nina Salabert-Le
    Poirier, Nicolas
    Vasseur, Berangere
    Costantini, Dominique
    Fromond, Claudia
    Delord, Jean-Pierre
    CANCER RESEARCH, 2022, 82 (12)
  • [48] Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
    Yap, Timothy A.
    O'Carrigan, Brent
    Penney, Marina S.
    Lim, Joline S.
    Brown, Jessica S.
    Luken, Maria J. de Miguel
    Tunariu, Nina
    Perez-Lopez, Raquel
    Rodrigues, Daniel Nava
    Riisnaes, Ruth
    Figueiredo, Ines
    Carreira, Suzanne
    Hare, Brian
    McDermott, Katherine
    Khalique, Saira
    Williamson, Chris T.
    Natrajan, Rachael
    Pettitt, Stephen J.
    Lord, Christopher J.
    Banerji, Udai
    Pollard, John
    Lopez, Juanita
    de Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) : 3195 - +
  • [49] A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of unclear export (SINE) in patients (pis) with advanced solid tumors
    Mau-Soerensen, Morten
    Razak, Albiruni R. A.
    Shields, Anthony Frank
    Gabrall, Nashat Y.
    Gereeltano, John F.
    Shacham, Sharon
    Lassen, Ulrlk Niels
    Rashal, Taml
    Cooksoy, Jennifer
    Landosman, Yosof
    Pond, Gregory
    Oza, Amit M.
    Kauffman, Michael
    Siu, Lillian L.
    Bedard, Philippe L.
    Mahaseth, Hemchandra
    Mlrza, Mansoor Raza
    Mahipal, Arnit
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors
    Britten, Carolyn D.
    Garrett-Mayer, Elizabeth
    Chin, Steven H.
    Shirai, Keisuke
    Ogretmen, Besim
    Bentz, Tricia A.
    Brisendine, Alan
    Anderton, Kate
    Cusack, Susan L.
    Maines, Lynn W.
    Zhuang, Yan
    Smith, Charles D.
    Thomas, Melanie B.
    CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4642 - 4650
12345